**The absence of merger or acquisition discussions between Merck and Moderna underpins the 85.3% market-implied probability of no 2026 deal.** Their longstanding 50/50 cost- and profit-sharing partnership on intismeran autogene (V940/mRNA-4157) plus Keytruda continues to advance without signals of consolidation. Positive August 19, 2026, Phase 3 INTerpath-001 results in resected high-risk melanoma—meeting recurrence-free and distant metastasis-free survival endpoints—drove sharp gains in Moderna shares and reinforced the existing arrangement rather than prompting acquisition talks. Merck has instead pursued separate oncology bolt-ons, such as the Terns Pharmaceuticals deal, while Moderna focuses on scaling its independent mRNA platform. Key near-term catalysts include regulatory filing discussions and additional trial readouts in lung, kidney, and bladder cancers, but these developments align with continued collaboration rather than full integration.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertJa
12% Chance
NEU
NEU
31. Dez. 2026
Ja
12% Chance
NEU
NEU
31. Dez. 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.**The absence of merger or acquisition discussions between Merck and Moderna underpins the 85.3% market-implied probability of no 2026 deal.** Their longstanding 50/50 cost- and profit-sharing partnership on intismeran autogene (V940/mRNA-4157) plus Keytruda continues to advance without signals of consolidation. Positive August 19, 2026, Phase 3 INTerpath-001 results in resected high-risk melanoma—meeting recurrence-free and distant metastasis-free survival endpoints—drove sharp gains in Moderna shares and reinforced the existing arrangement rather than prompting acquisition talks. Merck has instead pursued separate oncology bolt-ons, such as the Terns Pharmaceuticals deal, while Moderna focuses on scaling its independent mRNA platform. Key near-term catalysts include regulatory filing discussions and additional trial readouts in lung, kidney, and bladder cancers, but these developments align with continued collaboration rather than full integration.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Markt eröffnet: Aug 19, 2026, 3:58 PM ET
Volumen
$467Enddatum
1. Jan. 2027Markt eröffnet
Aug 19, 2026, 3:58 PM ETAbwickler
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.**The absence of merger or acquisition discussions between Merck and Moderna underpins the 85.3% market-implied probability of no 2026 deal.** Their longstanding 50/50 cost- and profit-sharing partnership on intismeran autogene (V940/mRNA-4157) plus Keytruda continues to advance without signals of consolidation. Positive August 19, 2026, Phase 3 INTerpath-001 results in resected high-risk melanoma—meeting recurrence-free and distant metastasis-free survival endpoints—drove sharp gains in Moderna shares and reinforced the existing arrangement rather than prompting acquisition talks. Merck has instead pursued separate oncology bolt-ons, such as the Terns Pharmaceuticals deal, while Moderna focuses on scaling its independent mRNA platform. Key near-term catalysts include regulatory filing discussions and additional trial readouts in lung, kidney, and bladder cancers, but these developments align with continued collaboration rather than full integration.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volumen
$467Enddatum
1. Jan. 2027Markt eröffnet
Aug 19, 2026, 3:58 PM ETAbwickler
0x65070BE91...**The absence of merger or acquisition discussions between Merck and Moderna underpins the 85.3% market-implied probability of no 2026 deal.** Their longstanding 50/50 cost- and profit-sharing partnership on intismeran autogene (V940/mRNA-4157) plus Keytruda continues to advance without signals of consolidation. Positive August 19, 2026, Phase 3 INTerpath-001 results in resected high-risk melanoma—meeting recurrence-free and distant metastasis-free survival endpoints—drove sharp gains in Moderna shares and reinforced the existing arrangement rather than prompting acquisition talks. Merck has instead pursued separate oncology bolt-ons, such as the Terns Pharmaceuticals deal, while Moderna focuses on scaling its independent mRNA platform. Key near-term catalysts include regulatory filing discussions and additional trial readouts in lung, kidney, and bladder cancers, but these developments align with continued collaboration rather than full integration.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen